Gut microbe may improve fatty liver

Due to the central role of liver in the whole body metabolism, fatty liver is a major health problem. In Finland alone, it affects around 1,000,000 people of the general population and has an occurrence of 90% among obese individuals. Humans with high liver fat content had less F. prausnitzii and more inflammation in the subcutaneous adipose tissue. The researchers, therefore, decided to study whether oral F. prausnitzii treatment would decrease hepatic fat content in high-fat fed mice that serve as a model for fatty liver. The results were very promising. Compared to the high-fat control mice, F. prausnitzii-treated mice had lower hepatic fat content, AST and ALT, as well as increased fatty-acid oxidation.
In addition, hepatic lipidomic analyses revealed decreases in several species of triacylglycerols, phospholipids and cholesteryl esters. Expression of adiponectin, which is one of the main beneficial mediators of metabolism, was increased in the visceral adipose tissue. While the F. prausnitzii-treated mice, in fact, had more subcutaneous fat, the fat was healthy as it was more insulin sensitive and less inflamed. Interestingly, F. prausnitzii treatment increased muscle mass, which may be linked to enhanced mitochondrial respiration. This is an issue that, according to Pekkala, definitely should be studied further.
These findings tentatively suggest that fatty liver might be treated with F. prausnitzii. Unfortunately, the potential therapeutic bacteria are not yet accepted for treatment purposes in humans. In addition, F. prausnitzii is strictly anaerobic and difficult to grow, why the researchers doubt that it could be delivered alive to humans, like e.g. lactic acid bacteria. Therefore, the researchers now aim at discovering alternative, natural ways, such as diets or prebiotics to increase the natural abundance of this bacterium in the host organism to treat fatty liver.
An article of the results of the research was published in the ISME Journal. The research was based on the earlier findings of the researchers in a human cohort, which were published in the Journal of Hepatology in 2014.
for more information visit our product website: Buy Vidalista CT 20 mg Online 
Location: United States

Comments

Post a Comment

Popular posts from this blog

Inflammatory bowel disease, nonalcoholic fatty liver disease may be linked, suggests research

A steady rise in obesity in a patient population that has traditionally been underweight led Bincy Abraham, M.D., at Houston Methodist Hospital, to focus her research on two diseases seen as rising epidemics in the United States. Abraham's team published findings in  Inflammatory Bowel Diseases® (IBD Journal ), showing IBD patients who were also diagnosed with nonalcoholic fatty liver disease were older and lived with IBD longer. They also found patients with the combined IBD/NAFLD diagnosis had fewer metabolic risk factors than patients with NAFLD alone. Abraham's next step is to determine if there are factors associated with IBD that lead to the development of nonalcoholic fatty liver disease. Abraham, director of the inflammatory bowel disease program at Houston Methodist Hospital, led a retrospective study of more than 400 of her patients separated into three groups -- 1) patients with both IBD and NAFLD; 2) patients with inflammatory bowel disease; and 3) patients wi...
Read more

Expanding waistlines and metabolic syndrome: Researchers warn of new 'silent killer'

In a commentary published in the  Journal of Cardiovascular Pharmacology and Therapeutics , the authors describe how being overweight and obesity contribute to metabolic syndrome, which affects 1 in 3 adults and about 40 percent of adults aged 40 and older. Clinicians have traditionally evaluated each of the major risk factors contributing to metabolic syndrome on an individual basis. There is evidence, however, that the risk factors are more than just the sum of their parts. "The major factor accelerating the pathway to metabolic syndrome is overweight and obesity," said Charles H. Hennekens, M.D., Dr.P.H., the first Sir Richard Doll Professor and senior academic advisor to the dean who senior authored the paper with Dawn H. Sherling, M.D., first author and an assistant professor of integrated medical science, and Parvathi Perumareddi, D.O., an assistant professor of integrated medical science, all faculty members in FAU's Charles E. Schmidt College of Medicine. ...
Read more